Relapse in patients with schizophrenia: A comparison between risperidone and haloperidol

Revista Brasileira de Psiquiatria

Volumn 25, Issue 4, 2003, Pages 220-223

  De Sena, Eduardo Pondé ^a,b   Santos Jesus, Rogério ^a   Miranda Scippa, Ângela ^a   De Castro Quarantini, Lucas ^a   De Oliveira, Irismar Reis ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b NONE   (Brazil)

Author keywords

Antipsychotic; Haloperidol; Relapse prevention; Risperidone; Schizophrenia

Indexed keywords

HALOPERIDOL; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0242486448     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-44462003000400007     Document Type: Article

References (30)

1. Buckley PF. Treatment of schizophrenia: let's talk dollars and sense. Am J Manag Care 1998;4:369-83.
2. Rice DP, The economic impact of schizophrenia. J Clin Psychiatry 1999;60:Suppl 1:4-6.
3. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995:21:419-29.
4. Davis JM. Overview; maintenance therapy in psychiatry, I: schizophrenia. Am J Psychiatry 1975;132:1237-45.
5. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979;36:1283-94.
6. Hogarty GE, Ulrich RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatry Res 1998;32:243-50.
7. Andreasen NC. Symptoms, signs and diagnosis of schizophrenia. Lancet 1995;346:477-81.
8. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;17:325-51.
9. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999;46:1396-408.
10. Herz MI, Lamberti JS, Mintz J, Scott R, O'Dell SP, Mc Cartan L, et al. A program for relapse prevention in schizophrenia: a controlled study. Arch Gen Psychiatry 2000;57:277-83.
11. Ayuso-Gutierrez JL, del Rio Vega J. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997;28:199-206.
12. Janssen PAJ, Niemegeers, CJE, Awouters F, Schellekens KH, Megens AAHP, Meert TF Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685-93.
13. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166(6):712-26.
14. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEvan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacology 1993;13:25-40.
15. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
16. De Oliveira, Miranda-Scippa AM, de Sena EP, Pereira EL, Ribeiro MG, de Castro-e-Silva E, et al. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. J Clin Pharm Ther 1996;21:349-58.
17. Song F. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J Psychopharmacol 1997;11:65-71.
18. Davies A, Adena MA, PC, Keks NA, Catts SV, Lambert T, Scweitzer I. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin Ther 1998;20(1):58-71.
19. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-46.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders [revised], 3rd edition. Washington (DC): APA; 1987.
21. Lima MS, Mari JJ, Trefiglio RP, Bacaltchuk J. Impacto do uso da risperidona na hospitalização de pacientes esquizofrênicos: estudo retrospectivo em três cidades brasileiras. J Bras Psiq 1999;48:461-4.
22. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57:53-60.
23. Sheitman BB, Lee H, Strauss R, Lieberman JA. The evaluation and treatment of first-episode psychosis. Schizophr Bull 1997;23:653-61.
24. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P. Reduction of hospital days in chronic patients who have schizophrenia treated with risperidone: a retrospective study. Clin Ther 1993;15:917-26.
25. Csernansky JG, Mahmoud R, Brenner R for the Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-21.
26. Hogarty GE. Prevention of relapse in chronic schizophrenic patients. J Clin Psychiatry 1993;54(3 Suppl): 18-23.
27. Schooler NR, Keith SJ, Severe JB. Matthew SM, Bellack AS, Glick ID, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. Arch Gen Psychiatry 1997;54:453-63.
28. Rabinowitz J, Davidson M. Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis. Schizophr Res 2001;50:89-93.
29. Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999;156:863-8.
30. Rabinowitz J, Lichtenber P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine or conventional neuroleptics. Am J Psychiatry 2001;158:266-9.